An epidemiological survey of vulvovaginal candidiasis in Italy

      Abstract

      Eight Italian hospital or University gynecology clinics participated in a prospective survey of patients with culture-confirmed symptomatic vulvovaginal candidiasis (VVC) (October 1999 to March 2001). Of 1138 patients recruited in the study, 931 were evaluable. A recent history of VVC was documented in 43.5% patients (358/823) with a mean number of 2.9±2.7 episodes per patient (N=302). A total of 77 patients (10.0%) had a history of recurrent VVC (four and more episodes in a 12-month period). The most frequent associated factors were related to life style: synthetic fabric underwear, vaginal douching and bike, training bike and motorbike (about 1/3 each). Oral contraception was found in 20.8% patients, recent antibiotic use in 15.9% patients, current pregnancy concerned 10.3% patients while 3.4% patients were taking hormonal replacement therapy. Diabetes, corticosteroids or HIV were rarely encountered. Yeast was documented by direct microscopy in 78.3% patients (448/572). A positive culture was obtained in 98.3% patients (909/925). Candida albicans was the predominant species (77.1%), followed by Candida glabrata (14.6%) and Candida krusei (4.0%). With the exception of one center with a lower proportion of C. albicans, this latter represented between 75 and 85% of the isolates. Overall, this study confirmed the preponderant role played by C. albicans in either sporadic and recurrent VVC.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Sobel J.D.
        • Faro S.
        • Force R.W.
        • et al.
        Vulvovaginal candidiasis: epidemiologic, diagnostic and therapeutic considerations.
        Am. J. Obstet. Gynecol. 1998; 178: 203-211
        • Foxman B.
        • Barlow R.
        • D’Arcy H.
        • Gillespie B.
        • Sobel J.D.
        Candida vaginitis: self-reported incidence and associated costs.
        Sex Transm. Dis. 2000; 27: 230-235
        • Sobel J.D.
        Vulvovaginitis, when Candida becomes a problem.
        Sex Transm. Dis. 1998; 16: 763-768
        • Lefèvre J.C.
        • Averous S.
        • Bauriaud R.
        • Blanc C.
        • Bertrand M.A.
        • Lareng M.B.
        Lower genital tract infections in women: comparison of clinical and epidemiologic findings with microbiology.
        Sex Transm. Dis. 1988; 15: 110-113
        • Spinillo A.
        • Capuzzo E.
        • Gulminetti R.
        • Marone P.
        • Colonna L.
        • Piazzi G.
        Prevalence and risk factors for fungal vaginitis caused by non-albicans species.
        Am. J. Obstet. Gynecol. 1997; 176: 138-141
        • Reef S.E.
        • Levine W.C.
        • McNeil M.M.
        • et al.
        Treatment options for vulvovaginal candidiasis, 1993.
        Clin. Infect. Dis. 1995; 20: S80-S90
        • Walker P.P.
        • Reynolds M.T.
        • Ashbee H.R.
        • Brown C.
        • Evans E.G.
        Vaginal yeasts in the era of “over the counter” antifungals.
        Sex Transm. Infect. 2000; 76: 437-438
        • Morace G.
        • Sanguinetti M.
        • Posteraro B.
        • et al.
        Vulvovaginal yeast infections: microbiology, pregnancy and correlation with symptoms.
        Igiene Moderna. 1999; 112: 275-284
        • Otero L.
        • Palacio V.
        • Carreòo F.
        • Méndez F.J.
        • Vàsquez F.
        Vulvovaginal candidiasis in female sex workers.
        Int. J. STD AIDS. 1998; 9: 526-530
        • El-Din S.S.
        • Reynolds M.T.
        • Ashbee H.R.
        • Barton R.C.
        • Evans E.G.
        An investigation into the pathogenesis of vulvo-vaginal candidosis.
        Sex Transm. Infect. 2001; 77: 179-183
        • Parazzini F.
        • Di Cintio E.
        • Chiantera V.
        • Guaschino S.
        Determinants of different Candida species infections of the genital tract in women. Sporachrom Study Group.
        Eur. J. Obstet. Gynecol. Reprod. Biol. 2000; 93: 141-145
        • Arzeni D.
        • Del Poeta M.
        • Simonetti O.
        • et al.
        Prevalence and antifungal susceptibility of pathogenic vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy.
        Eur. J. Epidemiol. 1997; 13: 447-450
        • Agatensi L.
        • Franchi F.
        • Mondello F.
        • et al.
        Vaginopathic and proteolytic Candida species in outpatients attending a gynaecologic clinic.
        J. Clin. Pathol. 1991; 44: 826-830
        • Odds F.C.
        • Bernaerts R.
        Chromagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species.
        J. Clin. Microbiol. 1994; 32: 1923-1929
        • Schaaf V.M.
        • Perez-Stable E.J.
        • Borchardt K.
        The limited value of symptoms and signs in the diagnosis of vaginal infections.
        Arch. Int. Med. 1990; 150: 1929-1933
      1. 1998 guidelines for treatment of sexually transmitted diseases. MMWR 199847(RR-1).

        • Sherrard J.
        European guideline for the management of vaginal discharge.
        Int. J. STD AIDS. 2001; 12: 73-77
        • Spinillo A.
        • Capuzzo E.
        • Acciano S.
        • De Santolo A.
        • Zara F.
        Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis.
        Am. J. Obstet. Gynecol. 1999; 180: 14-17
        • Helfgott A.
        • Eriksen N.
        • Bundrick C.M.
        • Lorimor R.
        • Van Eckhout B.
        Vaginal infections in human immunodeficiency virus-infected women.
        Am. J. Obstet. Gynecol. 2000; 183: 347-355
        • Spinillo A.
        • Carratta L.
        • Pizzoli G.
        • et al.
        Recurrent vaginal candidiasis. Results of a cohort study of sexual transmission and intestinal reservoir.
        J. Reprod. Med. 1992; 37: 343-347
        • Mathema B.
        • Cross E.
        • Dun E.
        • et al.
        Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals.
        Clin. Infect. Dis. 2001; 33: E23-27
        • Odds F.C.
        • Davidson A.
        “Room temperature” use of Chromagar Candida.
        Diagn. Microbiol. Infect. Dis. 2000; 38: 147-150
        • Sobel J.D.
        • Kapernick P.S.
        • Zervos M.
        • et al.
        Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole.
        Am. J. Obstet. Gynecol. 2001; 185: 363-369
        • Vazquez J.A.
        • Sobel J.D.
        • Demitriou R.
        • Vaishampayan J.
        • Lynch M.
        • Zervos M.J.
        Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis.
        J. Infect. Dis. 1994; 170: 1566-1569
        • Maffei C.M.
        • Paula C.R.
        • Mazzocato T.S.
        • Franceschini S.
        Phenotype and genotype of Candida albicans strains isolated from pregnant women with recurrent vaginitis.
        Mycopathologia. 1997; 137: 87-94
        • Fidel P.L.
        • Sobel J.D.
        Immunopathogenesis of recurrent vulvovaginal candidiasis.
        Clin. Microbiol. Rev. 1996; 9: 335-348